PT-141 (Bremelanotide): Complete Guide to the Research and Safety Data

According to the FDA label, bremelanotide non-selectively activates several melanocortin receptor subtypes, in this order of potency: MC1R, MC4R, MC3R, MC5R, MC2R. At clinical exposures, binding at MC1R and MC4R is considered most relevant. The label states plainly that the mechanism by which it improves low sexual desire is unknown, and notes that MC1R on melanocytes drives melanin production and pigmentation.^[1]

The working hypothesis centres on MC4R in the hypothalamus. A 2022 review summarises animal evidence that bremelanotide activates presynaptic MC4R on neurons of the medial preoptic area, increasing dopamine release in a region tied to sexual motivation. Structural work supports direct receptor engagement: cryo-electron microscopy structures published in 2021 show bremelanotide bound to MC4R in complex with its Gs protein.^[16][17]

The evidence points to a central rather than a blood-flow effect. In an 18-woman crossover study of a single intranasal dose, more women reported moderate or high sexual desire after bremelanotide than after placebo, yet vaginal vasocongestion measured during an erotic video did not change significantly.^[14]

MC4R also regulates appetite. In two small phase 1 trials in premenopausal women with obesity, repeated daily bremelanotide cut calorie intake by roughly 400 kcal a day and, over 16 days, body weight by 1.3 kg more than placebo. It is not approved for weight management.^[18][1]

In female rats, PT-141 selectively increased solicitation, the appetitive behaviours a female uses to initiate mating, without changing lordosis, pacing or general motor activity; the authors framed this as a model of desire rather than reflex. Earlier work had shown erections in male rats and non-human primates, and activation of hypothalamic neurons after systemic dosing.^[15][11]

The first human studies were in men. Intranasal PT-141 in healthy men and in men with mild-to-moderate erectile dysfunction produced statistically significant erectile responses versus placebo, with a median time to peak concentration of 30 minutes and a half-life of about two hours; flushing and nausea were the most common adverse events. A subcutaneous study also reported erectile responses in men who had responded inadequately to sildenafil.^[12][13]

Two 2008 bremelanotide trials from a single investigator should be set aside. The Journal of Sexual Medicine retracted one, in women with arousal disorder, after the author did not supply original data to answer reviewers' concerns about its methods and statistics. The Journal of Urology has placed an expression of concern on the other, in men who had not responded to sildenafil.^[23][24]

RECONNECT was two identical 24-week, randomised, double-blind, placebo-controlled trials (studies 301 and 302) in premenopausal women with hypoactive sexual desire disorder. Of 1,267 women randomised, most were white (85.6%) and enrolled at US sites (96.6%), with a mean age of 39. Participants self-administered 1.75 mg of bremelanotide or placebo under the skin as needed, before anticipated sexual activity.^[4][1]

Both trials met their two co-primary endpoints. Compared with placebo, scores on the desire domain of the Female Sexual Function Index rose by 0.30 and 0.42 points, and distress about low desire fell by 0.37 and 0.29 points on a single 0-to-4 questionnaire item. For scale, the desire domain runs from 1.2 to 6.0, and the label reports mean changes of 0.5 to 0.6 on bremelanotide against 0.2 on placebo.^[4][1]

Retention was a problem. The label reports that 40% of bremelanotide patients versus 13% on placebo left study 1 early, and 39% versus 25% left study 2. In the 52-week open-label extension, 684 of 856 eligible women enrolled and 272 completed it; the investigators reported no new safety signals and sustained score improvements, although that phase had no control group.^[1][5]

The size and meaning of the effect are contested in peer-reviewed journals. A 2021 re-analysis built on the FDA application data found results similar to the published trials, but highlighted what had not been reported: discontinuation for adverse events was far higher on bremelanotide (odds ratio 11.98, number needed to harm 6), and on a measure combining trial completion with entry into the extension, participants preferred placebo. The trial investigators published a rebuttal.^[19][20]

A 2024 follow-up argued that the desire and distress measures have little validity evidence in women with HSDD, and that previously unpublished trial outcomes showed effects ranging from nil to small. The phase 2b trial's primary endpoint, satisfying sexual events, rose by 0.7 a month against 0.2 on placebo in the pooled higher-dose groups, but it was not a primary endpoint in phase 3. A 2021 Drug and Therapeutics Bulletin analysis of the approval data concluded that bremelanotide led to no additional enjoyable sexual experiences.^[21][8][22]

What is not in dispute: the phase 3 gains on the co-primary questionnaires were statistically significant and modest, tolerability (above all nausea) drove many dropouts, and none of the data concern men, postmenopausal women or healthy people seeking enhancement. Online claims of dramatic libido effects are not what the controlled trials show.^[4][1][19]

The label's pooled phase 3 table lists nausea in 40.0% of bremelanotide patients versus 1.3% on placebo, flushing in 20.3% versus 0.3%, injection-site reactions in 13.2% versus 8.4%, headache in 11.3% versus 1.9% and vomiting in 4.8% versus 0.2%. Most events were mild (31%) or moderate (40%) and transient; serious adverse reactions were reported in 1.1% versus 0.5%.^[1]

Nausea was the defining problem. It usually began within an hour and lasted about two hours, affected 21% of patients after the first dose and about 3% after later doses, led 13% to need an anti-nausea drug and caused 8% to leave the trials. In a phase 4 study of 228 healthy women, pre-treatment with ondansetron did not reduce it. Overall, 18% of bremelanotide patients versus 2% on placebo stopped because of adverse reactions.^[1]

A 2022 review of the full development programme, covering 3,500 subjects in 43 completed studies with phase 3 exposure of up to 18 months, reported no deaths and a few serious adverse events, and confirmed nausea as the most common reason for stopping.^[6]

Bremelanotide raises blood pressure after each dose. The label reports maximal increases of 6 mmHg systolic and 3 mmHg diastolic, peaking two to four hours after dosing, with heart rate falling by up to 5 beats per minute and values usually back to baseline within 12 hours. An ambulatory-monitoring trial in 397 women found systolic rises of roughly 2 to 3 mmHg over placebo in the first four hours. The label contraindicates it in uncontrolled hypertension or known cardiovascular disease.^[1][7]

Skin darkening follows from MC1R activity. In phase 3, focal hyperpigmentation of the face, gums or breasts occurred in 1% of patients using up to eight doses a month and in no placebo patients. In a separate study, 38% developed it after daily dosing for eight days and a further 14% after eight more days; darker skin carried higher risk, and resolution was not confirmed in every case after stopping.^[1][6]

The label also records one case of acute hepatitis in the open-label extension, with liver enzymes above 40 times the upper limit of normal, in which a role for the drug could not be excluded. Bremelanotide may slow gastric emptying and significantly lowers exposure to oral naltrexone; indomethacin levels were also reduced. It caused fetal harm in dogs and developmental delays in mice, human pregnancy data are too few to judge, and two-year rodent studies found no significant increase in tumours.^[1][6]

The FDA approved bremelanotide injection (Vyleesi, NDA 210557) on 21 June 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder that is not due to a co-existing medical or psychiatric condition, relationship problems or the effects of a medication. The label states it is not indicated for postmenopausal women, for men, or to enhance sexual performance.^[2][1]

It was the second FDA-approved drug for this diagnosis, after flibanserin in 2015. In the European Union there is no EMA authorisation: a September 2026 search of the European Medicines Agency's medicines database returned no entry for bremelanotide, whether authorisation, application or European Public Assessment Report (EPAR).^[22][3]

Outside regulated channels, bremelanotide circulates alongside Melanotan II. A forensic toxicology study used high-resolution mass spectrometry to identify both peptides in samples seized by police together with anabolic steroids and other performance- and image-enhancing drugs, a reminder that the contents of an unregulated vial cannot be assumed.^[25]

Peptyds supplies PT-141 as a lyophilised research peptide for in-vitro laboratory research only, documented with a batch-specific certificate of analysis under the same quality protocol as the rest of the catalogue. We do not present it as a treatment for low desire, an enhancement product or a stand-in for the prescription medicine.^[1][3]

For laboratories, the published record points to practical checks: confirm identity by mass spectrometry and purity by HPLC on the batch document, because bremelanotide and Melanotan II are close structural relatives that turn up in the same unregulated supply.^[25][10]

Anyone weighing personal use should keep the documented facts in view: a narrow approved indication that excludes men and postmenopausal women, small average benefits, frequent nausea, blood-pressure effects and pigmentation that may not reverse. Decisions about clinical use belong with a qualified prescriber.^[1][6]